Accepted for Publication: February 20, 2014.
Published Online: April 28, 2014. doi:10.1001/jamaneurol.2014.446.
Study concept and design: Mattsson, Insel, Nosheny, Tosun, Trojanowski, Weiner.
Acquisition, analysis, or interpretation data: Mattsson, Insel, Tosun, Trojanowski, Shaw, Jack, Donohue, Weiner.
Drafting of the manuscript: Mattsson, Insel, Tosun, Trojanowski, Weiner.
Critical revision of the manuscript for important intellectual content: Insel, Nosheny, Tosun, Trojanowski, Shaw, Jack, Donohue, Weiner.
Statistical analysis: Mattsson, Insel, Nosheny, Tosun, Trojanowski, Donohue.
Obtained funding: Trojanowski, Weiner.
Administrative, technical, or material support: Trojanowski, Shaw, Jack.
Study supervision: Tosun, Trojanowski, Weiner.
Conflict of Interest Disclosures: Dr Trojanowski may accrue revenue in the future on patents submitted by the University of Pennsylvania on which he is coinventor, has received revenue from the sale of Avid to Eli Lilly and Company as coinventor on imaging-related patents submitted by the University of Pennsylvania, and is the William Maul Measey–Truman G. Schnabel, Jr, MD, Professor of Geriatric Medicine and Gerontology. Dr Shaw previously was a consultant for Innogenetics, collaborates on quality assessment activities as part of the Alzheimer’s Disease Neuroimaging Initiative, and serves as a consultant to Janssen Research & Development LLC on biomarker studies. Dr Jack provides consulting services for Siemens Healthcare and Janssen Research & Development LLC, holds the Alexander Family Alzheimer’s Disease Research Professorship of the Mayo Foundation, and is the recipient of research grants R01-AG011378, R01-AG041851, R01-AG037551, U01-HL096917, U01-AG032438, and U01-AG024904 from the National Institutes of Health. Dr Weiner has stock options in Synarc Inc and Elan Corporation; serves as an associate editor of Alzheimer’s & Dementia; has served on scientific advisory boards for Pfizer Inc and BOLT International; has received honoraria from Pfizer Inc, Tohoku University, and Danone Trading BV; has research support from Merck & Co Inc, Avid, the Department of Defense, and the Department of Veterans Affairs; has received funding for travel from Pfizer Inc, the International Conference on Alzheimer’s and Parkinson’s Diseases, Paul Sabatier University, Novartis, Tohoku University, MCI Group, France, Travel eDreams Inc, Neuroscience School of Advanced Studies, Danone Trading BV, and the Clinical Trials on Alzheimer’s Disease ANT Congrès; and has been a consultant for Pfizer Inc, Janssen Research & Development LLC, KLJ Associates, Easton Associates, Harvard University, inThought, INC Research LLC, the Alzheimer’s Drug Discovery Foundation, Sanofi Groupe, and the University of California, Los Angeles. No other disclosures were reported.
Funding/Support: Data collection and sharing for this project were funded by grant U01-AG024904 from the National Institutes of Health to the Alzheimer’s Disease Neuroimaging Initiative (ADNI). The ADNI is funded by the National Institute on Aging, the National Institute of Biomedical Imaging and Bioengineering, and through generous contributions from Abbott, AstraZeneca AB, Bayer Schering Pharma AG, Bristol-Myers Squibb, Eisai Global Clinical Development, Elan Corporation, Genentech, GE Healthcare, GlaxoSmithKline, Innogenetics, Johnson & Johnson, Eli Lilly and Company, Medpace Inc, Merck and Co Inc, Novartis AG, Pfizer Inc, F. Hoffman–La Roche, Schering-Plough, and Synarc Inc, as well as by its nonprofit partners the Alzheimer’s Association and the Alzheimer’s Drug Discovery Foundation, with participation from the US Food and Drug Administration. Private sector contributions to the ADNI are facilitated by the Foundation for the National Institutes of Health (www.fnih.org). The grantee organization is the Northern California Institute for Research and Education, and the study is coordinated by the Alzheimer’s Disease Cooperative Study at the University of California, San Diego. The ADNI data are disseminated by the Laboratory for Neuro Imaging at the University of California, Los Angeles. This research was also supported by grants P30-AG010129 and K01-AG030514 from the National Institutes of Health, the Swedish Research Council, Goteborgs Lakaresallskap, Svenska Lakaresallskapet, Sahlgrenska Universitetssjukhuset, Carl-Bertil Laurells Fond, and Klinisk Biokemi i Norden.
Role of the Sponsor: The funding sources had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.
Group Information: A complete list of the ADNI investigators can be found at http://adni.loni.usc.edu/wp-content/uploads/how_to_apply/ADNI_Acknowledgement_List.pdf. Data used in the preparation of this article were obtained from the ADNI database (http://adni.loni.usc.edu). As such, the investigators within the ADNI contributed to the design and implementation of ADNI and/or provided data but did not participate in the analysis or writing of this report.